Bristol-Myers Gives Results From an Analysis on its Phase 3 Checkmate Study, Says Opdivo in Combination with Yervoy Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma